US regulators approve HIV drug etravirine
Food and Drug Administration approves Drug etravirine for the treatment of HIV in adults who have failed treatment with other antiretrovirals.
By Agencies |
WASHINGTON: Tablets of the drug etravirine were approved by the regulatory Food and Drug Administration for the treatment of HIV infection in adults who have failed treatment with other antiretrovirals.
Sold under the trade name Intelence, etravirine is a non-nucleoside reverse transcriptase inhibitor, or NNRTI, that helps to block an enzyme that the human immunodeficiency virus needs to multiply, the FDA said Friday. It was approved for use in combination with other anti-HIV medications.
Etravirine can reduce the amount of HIV in the blood and increase white blood cells that help fight off other infections, the FDA said. It also may reduce the risk of death or infections that can occur with a weakened immune system.
The government gave etravirine a priority review, a status granted to medications aimed at treating serious or life-threatening conditions. Tibotec Pharmaceuticals Ltd., a unit of Johnson & Johnson, said last July that it had requested etravirine be placed on a fast track for review.
``This is another significant new product for many HIV-infected patients who are NNRTI-resistant and whose infections are not responding to currently available medications,'' said Dr. Debra B. Birnkrant, director of the FDA's Division of Antiviral Products.
The drug is distributed by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., a Johnson & Johnson company based in Bridgewater, New Jersey.
Sold under the trade name Intelence, etravirine is a non-nucleoside reverse transcriptase inhibitor, or NNRTI, that helps to block an enzyme that the human immunodeficiency virus needs to multiply, the FDA said Friday. It was approved for use in combination with other anti-HIV medications.
Etravirine can reduce the amount of HIV in the blood and increase white blood cells that help fight off other infections, the FDA said. It also may reduce the risk of death or infections that can occur with a weakened immune system.
The government gave etravirine a priority review, a status granted to medications aimed at treating serious or life-threatening conditions. Tibotec Pharmaceuticals Ltd., a unit of Johnson & Johnson, said last July that it had requested etravirine be placed on a fast track for review.
``This is another significant new product for many HIV-infected patients who are NNRTI-resistant and whose infections are not responding to currently available medications,'' said Dr. Debra B. Birnkrant, director of the FDA's Division of Antiviral Products.
The drug is distributed by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., a Johnson & Johnson company based in Bridgewater, New Jersey.
Download
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
